Title

5 Year Overall Survival of Triple Negative Breast Cancer: A Single Institution Experience.

Publication/Presentation Date

2016

Abstract

Background: Triple negative breast cancer (TNBC) involves any breast cancer that does not express the genes for estrogen and progesterone receptors (ER /PR) and Her2/neu. TNBC accounts for approximately 10- 20% of invasive breast cancers and this sub-type carries a poorer prognosis. TNBC are also frequently associated with BRCA mutations. We performed a retrospective review of TNBC that were seen at our institution, Lehigh Valley Health Network from 2005 to 2009 for survival and prevalence of BRCA mutation. Methods:Breast Cancer cases that presented to Lehigh Valley Health Network (LVHN) from 2005 to 2009 and which were triple negative, hormone receptors negative/Her2 unknown and hormone receptor/Her2 unknown were retrieved from tumor registry. Records of the above cases were reviewed and only the breast cancer cases that were triple negative were included for the study. Data was collected for age, stage on presentation, treatment received, survival and presence of BRCA mutation if genetic testing was performed. Results: 388 Charts were reviewed and 224 cases were found to be TNBC with age range of 29 to 88 years. Of the TNBC cases, 41 were stage 0, 72 cases were stage 1, 64 cases were stage 2, 24 cases were stage 3 and 23 cases were stage 4 on presentation. Overall 5 year survival rate was 78.6%. The 5 year survival rates stage wise included 92.7% for stage 0, 95.8% for stage 1, 78.1% for stage 2, 54.2% for stage 3 and 26.1% for stage 4. 172 charts were reviewed for genetic testing. 144 cases did not get tested. Out of 32 cases that were tested, 17 had wild type, 9 had BRCA1 mutant and 6 had BRCA2 mutant. Conclusions: 224 triple negative breast cancer cases were seen at LVHN from 2005 to 2009. Majority of cases presented as early stages, stage 0 to II. Age ranges of patients were 29 to 88 years. Overall 5 year survival for TNBC was 78.6%. Prevalence of BRCA mutation is 7.21% of the triple negative breast cancer cases. This is lower than that reported in literature where the prevelance of BRCA mutation is approximately 20% of TNBC. Possible reasons for this variation include age at diagnosis and patients' refusal for testing. Of the patients that were tested the prevalence was 46.88% and may be attributed to additinal high risk features such as age and family history.

Disciplines

Medical Sciences | Medicine and Health Sciences

Department(s)

Department of Medicine, Department of Medicine Faculty, Hematology-Medical Oncology Division

Document Type

Presentation

This document is currently not available here.

Share

COinS